Is PMN or PPCB more undervalued in 2026?

CirclFi compares ProMIS Neurosciences Inc. (PMN) and Propanc Biopharma, Inc. (PPCB) using 13 institutional-grade valuation models. PMN has a Quality of Company score of 4.2/10 while PPCB scores 3.7/10.

Which is a better buy — PMN or PPCB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PMN and PPCB valuations compare?

PMN at $10.87 and PPCB at $1.70 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PMN vs PPCB Valuation Comparison 2026 — Intrinsic Value Analysis

PMN

Biotechnology

ProMIS Neurosciences Inc.

Quality

4.2

out of 10

Value Trap

LOW

Price

$10.87

Last close

Models

6/13

Active

PPCB

Biotechnology

Propanc Biopharma, Inc.

Quality

3.7

out of 10

Value Trap

LOW

Price

$1.70

Last close

Models

6/13

Active

Model-by-Model Comparison

Model	Type	PMN Fair Value	PMN Upside	PPCB Fair Value	PPCB Upside
Bayesian DCF	Intrinsic	$6.79	-37.5%	$0.50	-70.8%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$10.85	-0.2%	$6.64	+290.6%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PMN vs PPCB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PMN vs PPCB — Which Stock Is More Undervalued?

PMN scores higher with a 4.2/10 quality rating vs PPCB's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing ProMIS Neurosciences Inc. (PMN) and Propanc Biopharma, Inc. (PPCB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PMN currently trades at $10.87 with a QOC of 4.2/10, while PPCB trades at $1.70 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).